MoonLake Immunotherapeutics (MLTX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $16.87: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 3.18; Below-average business quality.
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in... Read more
Sell if holding. Engine safety override at $16.87: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 3.18; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.6/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — MoonLake Immunotherapeutics
Latest news
- Needham Maintains Buy on MoonLake, Raises Price Target to $30 — benzinga May 12, 2026 positive
- FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars — benzinga May 11, 2026 positive
- HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $45 — benzinga May 11, 2026 positive
- Reported Sunday, MoonLake Secures FDA Alignment On Sonelokimab BLA Submission Plan, Holds $357.9M Cash With Runway Throu — benzinga May 11, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Volatile — 6.8% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.87: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 3.18; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $15.53. Score 4.6/10, moderate confidence.
Take-profit target: $24.03 (+46.2% upside). Prior stop was $15.53. Stop-loss: $15.53.
Quality below floor (1.7 < 4.0); Value-trap signals (2/5): Margin compression (op margin -11.0%), High leverage (D/E 1.8).
MoonLake Immunotherapeutics trades at a P/E of N/A (forward -4.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
23 analysts cover MLTX with a consensus score of 4.0/5. Average price target: $28.
What does MoonLake Immunotherapeutics do?MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory...
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.